SYS6051 / CSPC Pharma - LARVOL DELTA

SYS6051, a next-generation tissue factor-targeted antibody-drug conjugates for the treatment of TF-expressing malignancies (AACR 2025) - "Neither coagulation disorder nor skin rash was observed, superior to the historical toxicity data in NHP of the MTI-ADC. Taken together, SYS6051 has a wide therapeutic window because of promising efficacy, higher tolerability, stable PK profile, and could potentially provide benefits for the patients carrying TF positive malignancies."

Cervical Cancer • Oncology • Pancreatic Cancer • Solid Tumor